Take a look at John Flavin's interview on Yahoo Finance! John was interviewed by Julie Hyman and Josh Lipton to discuss GLP-1 and A.I.'s impact on life sciences - watch the full interview here: https://lnkd.in/grgggFpd
Great interview of John Flavin!
PMI Post Merger Integration | Change Management | Transformation | International Healthcare Industry | Cosmetics | Pharmaceutical | Life Sciences |
David Stuarts draws the life sciences environment in Life Science Leader to present the M&A outlook for 2024. He summarizes the life sciences as the most dynamic sector of the economy, highlighting its challenges and opportunities. Challenges: -Increased antitrust scrutiny -Inflation uncertainty and cost of capital -Geopolitical tensions. Opportunities: -The rise of new technologies -Growing demand for personalized medicine -Emerging markets expansion. https://lnkd.in/e7e6vSmz
What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:
RSM Consulting Principal, National Technology Risk Consulting Leader, Philadelphia Office Leader
What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:
Life Sciences l IT Consulting l Cybersecurity l AI l Cloud l Infrastructure l Accounting Automation
What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:
What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:
What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:
What's ahead for life sciences companies in 2024? Read the latest industry outlook from RSM senior analysts Amanda Laskey, Brian Winne, and Justin Culbertson:
Thoughts on this? >> Bye, Bye, Baltimore: GEN's Takeaways from ASGCT - Genetic Engineering & Biotechnology News >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #pharmaceutical #healthcare #competitivemarketing
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Bye, Bye, Baltimore: GEN's Takeaways from ASGCT - Genetic Engineering & Biotechnology News >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharma #competitivemarketing #pharmaceutical
Autoimmune Disease, Inflammation, and Oncology | Drug Discovery to IND | Expert in Cross-Functional Collaboration
4wGood story!